IMD-Pharma uncovers the mechanism of action of its new asset in Rheumatoid Arthritis. par IMDPharmaadm | Juin 7, 2023 | Non classé
IMD-Pharma signs a joint research agreement with the Inserm research unit U1291 (Infinity, PACID team, Toulouse). par IMDPharmaadm | Oct 20, 2022 | Non classé
IMD-Pharma validates in vitro and in vivo a new lead for Rheumatoid Arthritis. par IMDPharmaadm | Sep 20, 2022 | Non classé
IMD-Pharma hires Zakari Mouheb (biology), Laëtitia Lüdge (formulation) and Anthony Augé (chemistry) as apprentices in Master (12 months contract). par IMDPharmaadm | Sep 5, 2022 | Non classé
IMD-Pharma signs a joint research agreement with the CNRS research unit UMR 5623 (IMRCP, SMODD team, Toulouse). par IMDPharmaadm | Sep 4, 2022 | Non classé
IMD-Pharma obtains non-dilutive financing from BPI-France to support its growth. par IMDPharmaadm | Fév 11, 2022 | Non classé